Nurix Therapeutics (NRIX) Institutional Ownership

Of the 188 institutional investors that purchased Nurix Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: FMR LLC ($10.56M), BlackRock Inc. ($8.77M), General Atlantic L.P. ($4.90M), Vestal Point Capital LP ($4.27M), Perceptive Advisors LLC ($3.09M), Morgan Stanley ($2.62M), and Rubric Capital Management LP ($2.47M).

Institutional investors have bought a total of 49,029,871 shares in the last 24 months. This purchase volume represents approximately $952.61M in transactions.

Of the 46 institutional investors that sold Nurix Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: T. Rowe Price Investment Management Inc. ($2.07M), Commodore Capital LP ($1.67M), Millennium Management LLC ($1.34M), UBS Group AG ($1.23M), Pictet Asset Management Holding SA ($741.46K), Braidwell LP ($464.00K), and Amova Asset Management Americas Inc. ($376.33K).

Institutional investors have sold a total of 9,753,708 shares in the last 24 months. This volume of shares sold represents approximately $161.36M in transactions.